Management of the australianclinicaltrials.gov.au website has been transferred from NHMRC to the Commonwealth Department of Health. Disruption to site users as a consequence of this change should be minimal. Users should note that email notifications coming from the website will come from australianclinicaltrials@health.gov.au from Friday the 8th of April 2022. Any user experiencing difficulty as a result of this change should direct enquiries to australianclinicaltrials@health.gov.au for assistance.
Broad Health Condition Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Cancer
Blood
Specific Health ConditionHodgkin's
Leukaemia - Acute leukaemia
Leukaemia - Chronic leukaemia
Lymphoma (non Hodgkin's lymphoma) - High grade lymphoma
Lymphoma (non Hodgkin's lymphoma) - Low grade lymphoma
Myeloma
Other cancer types
Other blood disorders
Recruitment statusRecruiting
Recruitment Details
Recruitment State
VIC
Hospital
Cabrini Hospital - Malvern - Malvern
Postcode
3144 - Malvern
Anticipated date of first participant enrolment9/03/2020
Anticipated date of last participant enrolment9/03/2020
Has the study received ethics approval?Approved
Trial summary
The purpose of this study is to test a new screening tool to see if this tool helps the hospital meet patient’s supportive care needs. Supportive care includes physical, financial, emotional, family and practical support. Who is it for? You may be eligible for this study if you are aged 16 or over, you have a diagnosis of blood cancer and are receiving treatment. You may also be eligible for a part of the study if you have received treatment for a blood cancer in the past. Study details Participants in this study will be divided into two groups, depending on whether they are currently having treatment (called the prospective group), or received treatment in the past (the retrospective group). Both groups will complete screening tools, which involve a questionnaire. The retrospective group will complete a paper questionnaire and return by mail. The prospective group will complete the questionnaire at each appointment in a 12-month period. In addition to the questionnaire(s), all participants will also complete a satisfaction survey. It is hoped this research will demonstrate the usefulness of this screening process, and enable the needs of patients to be responded to more effectively.
Key inclusion criteria
Prospective arm: 1. Participants with a diagnosis of haematological malignancy (including, but not limited to, myeloma, lymphoma, leukaemia, myelodysplastic and myeloproliferative syndromes), attending the study centre 2. In receipt of treatment for their haematological malignancy during the twelve-month study period (including, but not limited to, parenteral chemotherapy and immunotherapy, oral chemotherapy/disease directed therapy or regular blood product transfusions) Retrospective arm: 1. Participants with a diagnosis of haematological malignancy (including, but not limited to, myeloma, lymphoma, leukaemia, myelodysplastic and myeloproliferative syndromes) 2. Attended the study centre between 28/05/19 - 27/05/2020 for treatment of their haematological malignancy
Minimum age16 Years
GenderBoth males and females
Can Healthy volunteers participate?No
Key exclusion criteria
For both prospective and retrospective arms, patients who are unable to speak or write the English language are not eligible for participation in this study.
Sponsor Primary Sponsor Type: Hospital
Primary Sponsor Name: Cabrini Hospital
Primary Sponsor Address: 183 Wattletree Rd Malvern VIC 3144
Primary Sponsor Country: Australia
Trial IDACTRN12620000303943
UTNU1111-1248-5402
Contact person for information and recruitmentA/Prof
Melita Kenealy
Cabrini Hospital
CHOC Level 2, 183 Wattletree Rd Malvern VIC 3144
+61 3 9500 9345melita.kenealy@thebloodunit.com.au
Australia